Protein corona acts as a protective shield against Fe3O4-PEG inflammation and ROS-induced toxicity in human macrophages

Toxicology Letters

Volumn 240, Issue 1, 2016, Pages 172-184

  Escamilla Rivera, V ^a   Uribe Ramirez M ^a   Gonzalez Pozos S ^a   Lozano, O ^b,c,d   Lucas, S ^b,c   De Vizcaya Ruiz, A ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b University of Namur   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

^d HOSPITAL ZAMBRANO HELLION   (Mexico)

Author keywords

Fe3O4 nanoparticles; Inflammation; Nanotoxicology; Protein corona

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON OXIDE; MACROGOL; NANOPARTICLE; PEPTIDES AND PROTEINS; PROTEIN CORONA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOMATERIAL; FERRIC ION; FERRIC OXIDE; MACROGOL DERIVATIVE; POVIDONE;

ARTICLE; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSICAL CHEMISTRY; SECRETION (PROCESS); TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; COATED MATERIALS, BIOCOMPATIBLE; FERRIC COMPOUNDS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOPARTICLES; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; POVIDONE; PROTEIN CORONA; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84947801594     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.10.018     Document Type: Article

References (60)

1. Adkins J.N., Varnum S.M., Auberry K.J., Moore R.J., Angell N.H., Smith R.D., Springer D.L., Pounds J.G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell. Proteomics 2002, 1:947-955.
2. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61:428-437.
3. Allen R.G., Tresini M. Oxidative stress and gene regulation. Free Radic. Biol. Med. 2000, 28:463-499.
4. Andreas K., Georgieva R., Ladwig M., Mueller S., Notter M., Sittinger M., Ringe J. Highly efficient magnetic stem cell labeling with citrate-coated superparamagnetic iron oxide nanoparticles for MRI tracking. Biomaterials 2012, 33:4515-4525.
5. Arbab A.S., Wilson L.B., Ashari P., Jordan E.K., Lewis B.K., Frank J.A. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 2005, 18:383-389.
6. Bulte J.W.M., Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004, 17:484-499.
7. Conner E.M., Grisham M.B. Inflammation, free radicals, and antioxidants. Nutrition 1996, 12:274-277.
8. Deng Z.J., Liang M., Monteiro M., Toth I., Minchin R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 2011, 6:39-44.
9. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2:469-478.
10. Dobrovolskaia M.A., McNeil S.E. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J. Controlled Release: Off. J. Controlled Release Soc. 2013, 172:456-466.
11. Dobrovolskaia M.A., Patri A.K., Zheng J., Clogston J.D., Ayub N., Aggarwal P., Neun B.W., Hall J.B., McNeil S.E. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2009, 5:106-117.
12. Dobrovolskaia M.A., Neun B.W., Man S., Ye X., Hansen M., Patri A.K., Crist R.M., McNeil S.E. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. Nanomed. Nanotechnol. Biol. Med. 2014, 10:1453-1463.
13. Duffield J.S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci. 2003, 104:27-38.
14. Ehrenberg M.S., Friedman A.E., Finkelstein J.N., Oberdörster G., McGrath J.L. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 2009, 30:603-610.
15. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9:1-14.
16. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
17. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J. Thrombosis Haemostasis: JTH 2009, 7(Suppl. 1):328-331.
18. Herold D.A., Keil K., Bruns D.E. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem. Pharmacol. 1989, 38:73-76.
19. Hu W., Peng C., Lv M., Li X., Zhang Y., Chen N., Fan C., Huang Q. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 2011, 5:3693-3700.
20. Hühn D., Kantner K., Geidel C., Brandholt S., De Cock I., Soenen S.J.H., Rivera_, Gil P., Montenegro J.-M., Braeckmans K., Müllen K., Nienhaus G.U., Klapper M., Parak W.J. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 2013, 7:3253-3263.
21. Kim J.A., Salvati A., Aberg C., Dawson K.A. Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety. Nanoscale 2014, 6:14180-14184.
22. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49:6288-6308.
23. Laurent S., Forge D., Port M., Roch A., Robic C., Vander Elst L., Muller R.N. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 2008, 108:2064-2110.
24. Lee D.E., Koo H., Sun I.C., Ryu J.H., Kim K., Kwon I.C. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 2012, 41:2656-2672.
25. Lesniak A., Fenaroli F., Monopoli M.P., Åberg C., Dawson K.A., Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 2012, 6:5845-5857.
26. Lesniak A., Salvati A., Santos-Martinez M.J., Radomski M.W., Dawson K.A., Åberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 2013, 135:1438-1444.
27. Levy M., Lagarde F., Maraloiu V.-A., Blanchin M.-G., Gendron F., Wilhelm C., Gazeau F. Degradability of superparamagnetic nanoparticles in a model of intracellular environment: follow-up of magnetic, structural and chemical properties. Nanotechnology 2010, 21:395103.
28. Liu Y., Schubert D. The specificity of neuroprotection by antioxidants. J. Biomed. Sci. 2009, 16:98.
29. 4 nanoparticles on the transcription of genes related to iron and osmosis homeostasis. Toxicol. Sci. 2013, 131:521-536.
30. Liu W., Rose J., Plantevin S., Auffan M., Bottero J.Y., Vidaud C. Protein corona formation for nanomaterials and proteins of a similar size: hard or soft corona?. Nanoscale 2013, 5:1658-1668.
31. Long T.C., Saleh N., Tilton R.D., Lowry G.V., Veronesi B. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ. Sci. Technol. 2006, 40:4346-4352.
32. Lozano O., Mejia J., Masereel B., Toussaint O., Lison D., Lucas S. Development of a PIXE analysis method for the determination of the biopersistence of SiC and TiC nanoparticles in rat lungs. Nanotoxicology 2012, 6:263-271.
33. Lozano O., Mejia J., Piret J.P., Saout C., Dogné J.M., Toussaint O., Lucas S. How does the deposited dose of oxide nanomaterials evolve in anin vitroassay?. J. Phys. Conf. Ser. 2013, 429:012013.
34. Lunov O., Syrovets T., Loos C., Beil J., Delacher M., Tron K., Nienhaus G.U., Musyanovych A., Mailänder V., Landfester K., Simmet T. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 2011, 5:1657-1669.
35. Mahmoudi M., Simchi A., Imani M., Milani A.S., Stroeve P. An in vitro study of bare and poly (ethylene glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: a new toxicity identification procedure. Nanotechnology 2009, 20:225104.
36. Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H., Budach V., Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011, 103:317-324.
37. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
38. Mejia J., Piret J.-P., Noël F., Masereel B., Toussaint O., Lucas S. Dose assessment of SiC nanoparticle dispersions during in vitro assays. J. Nanopart. Res. 2013, 15.
39. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., Dawson K.a. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133:2525-2534.
40. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012, 7:779-786.
41. Perez J.M., Josephson L., O'Loughlin T., Hogemann D., Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotechnol. 2002, 20:816-820.
42. Qiao R., Yang C., Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J. Mater. Chem. 2009, 19:6274-6293.
43. Raynal I., Prigent P., Peyramaure S., Najid A., Rebuzzi C., Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest. Radiol. 2004, 39:56.
44. Santoyo Salazar J., Perez L., de Abril O., Truong Phuoc L., Ihiawakrim D., Vazquez M., Greneche J.-M., Begin-Colin S., Pourroy G. Magnetic iron oxide nanoparticles in 10-40nm range: composition in terms of magnetite/maghemite ratio and effect on the magnetic properties. Chem. Mater. 2011, 23:1379-1386.
45. Schmidt D., Joyce E.J., Kao W.J. Fetal bovine serum xenoproteins modulate human monocyte adhesion and protein release on biomaterials in vitro. Acta Biomater. 2011, 7:515-525.
46. Sharma G., Kodali V., Gaffrey M., Wang W., Minard K.R., Karin N.J., Teeguarden J.G., Thrall B.D. Iron oxide nanoparticle agglomeration influences dose rates and modulates oxidative stress-mediated dose-response profiles in vitro. Nanotoxicology 2014, 8:663-675.
47. Singh R.P., Ramarao P. Accumulated polymer degradation products as effector molecules in cytotoxicity of polymeric nanoparticles. Toxicol. Sci. 2013, 136:131-143.
48. Singh N., Jenkins G.J., Nelson B.C., Marquis B.J., Maffeis T.G., Brown A.P., Williams P.M., Wright C.J., Doak S.H. The role of iron redox state in the genotoxicity of ultrafine superparamagnetic iron oxide nanoparticles. Biomaterials 2012, 33:163-170.
49. Soenen S.J., Himmelreich U., Nuytten N., De Cuyper M. Cytotoxic effects of iron oxide nanoparticles and implications for safety in cell labelling. Biomaterials 2011, 32:195-205.
50. Stroh A., Zimmer C., Gutzeit C., Jakstadt M., Marschinke F., Jung T., Pilgrimm H., Grune T. Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radi. Biol. Med. 2004, 36:976-984.
51. Teeguarden J.G., Hinderliter P.M., Orr G., Thrall B.D., Pounds J.G. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 2007, 95:300-312.
52. Wang F., Yu L., Monopoli M.P., Sandin P., Mahon E., Salvati A., Dawson K.A. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomed. Nanotechnol. Biol. Med. 2013, 9:1159-1168.
53. Weinstein J.S., Varallyay C.G., Dosa E., Gahramanov S., Hamilton B., Rooney W.D., Muldoon L.L., Neuwelt E.A. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2010, 30:15-35.
54. Weissleder R., Nahrendorf M., Pittet M.J. Imaging macrophages with nanoparticles. Nat Mater 2014, 13:125-138.
55. Wilhelm C., Lavialle F., Péchoux C., Tatischeff I., Gazeau F. Intracellular trafficking of magnetic nanoparticles to design multifunctional biovesicles. Small 2008, 4:577-582.
56. Yan Y., Gause K.T., Kamphuis M.M.J., Ang C.-S., O'Brien-Simpson N.M., Lenzo J.C., Reynolds E.C., Nice E.C., Caruso F. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano 2013, 7:10960-10970.
57. Yu M.K., Jeong Y.Y., Park J., Park S., Kim J.W., Min J.J., Kim K., Jon S. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. Engl. 2008, 47:5362-5365.
58. Zheng X., Baker H., Hancock W.S., Fawaz F., McCaman M., Pungor E. Proteomic analysis for the assessment of different lots of fetal bovine serum as a raw material for cell culture. Part IV. Application of proteomics to the manufacture of biological drugs. Biotechnol. Prog. 2006, 22:1294-1300.
59. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
60. Zhu M.-T., Wang B., Wang Y., Yuan L., Wang H.-J., Wang M., Ouyang H., Chai Z.-F., Feng W.-Y., Zhao Y.-L. Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: risk factors for early atherosclerosis. Toxicol. Lett. 2011, 203:162-171.